Zevra Therapeutics, Inc. Gain (Loss) on Disposition of Intangible Assets
Zevra Therapeutics, Inc. (ZVRA) reported Gain (Loss) on Disposition of Intangible Assets of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfIntangibleAssets · last filed 2026-08-05
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for the quarter ending 2026-03-31 was $43.31M.
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for the quarter ending 2025-12-31 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for the quarter ending 2025-09-30 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for fiscal 2025 was $148.32M.
- Zevra Therapeutics, Inc. gain (loss) on disposition of intangible assets for fiscal 2024 was $0.00.
| Period end | Gain (Loss) on Disposition of Intangible Assets 3 month | Gain (Loss) on Disposition of Intangible Assets 6 month | Gain (Loss) on Disposition of Intangible Assets 9 month | Gain (Loss) on Disposition of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $43.31M derived: sum of 3 quarters · filed 2026-08-05 | $43.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $43.31M 10-Q · filed 2026-05-06 | $43.31M derived: sum of 2 quarters · filed 2026-05-06 | $43.31M derived: sum of 3 quarters · filed 2026-05-06 | $191.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $148.32M derived: sum of 3 quarters · filed 2026-08-05 | $148.32M 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $148.32M derived: sum of 2 quarters · filed 2026-08-05 | $148.32M 10-Q · filed 2025-11-05 | $148.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $148.32M 10-Q · filed 2026-08-05 | $148.32M 10-Q · filed 2026-08-05 | $148.32M derived: sum of 3 quarters · filed 2026-08-05 | $148.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |